Pular para o conteúdo
Merck

Histone methyltransferase DOT1L controls state-specific identity during B cell differentiation.

EMBO reports (2021-01-08)
Muhammad Assad Aslam, Mir Farshid Alemdehy, Eliza Mari Kwesi-Maliepaard, Fitriari Izzatunnisa Muhaimin, Marieta Caganova, Iris N Pardieck, Teun van den Brand, Tibor van Welsem, Iris de Rink, Ji-Ying Song, Elzo de Wit, Ramon Arens, Heinz Jacobs, Fred van Leeuwen
RESUMO

Differentiation of naïve peripheral B cells into terminally differentiated plasma cells is characterized by epigenetic alterations, yet the epigenetic mechanisms that control B-cell fate remain unclear. Here, we identified a role for the histone H3K79 methyltransferase DOT1L in controlling B-cell differentiation. Mouse B cells lacking Dot1L failed to establish germinal centers (GC) and normal humoral immune responses in vivo. In vitro, activated B cells in which Dot1L was deleted showed aberrant differentiation and prematurely acquired plasma cell characteristics. Similar results were obtained when DOT1L was chemically inhibited in mature B cells in vitro. Mechanistically, combined epigenomics and transcriptomics analysis revealed that DOT1L promotes expression of a pro-proliferative, pro-GC program. In addition, DOT1L indirectly supports the repression of an anti-proliferative plasma cell differentiation program by maintaining the repression of Polycomb Repressor Complex 2 (PRC2) targets. Our findings show that DOT1L is a key modulator of the core transcriptional and epigenetic landscape in B cells, establishing an epigenetic barrier that warrants B-cell naivety and GC B-cell differentiation.

MATERIAIS
Número do produto
Marca
Descrição do produto

Roche
Streptavidin-AP conjugate, solution, pkg of 1 mL (1,000U)
Sigma-Aldrich
Anti-dimethyl-Histone H3 (Lys79) Antibody, clone NL59, rabbit monoclonal, culture supernatant, clone NL59, Upstate®